Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan

Background Type 2 diabetes is a risk factor for steatohepatitis and fibrosis. Non‐invasive liver stiffness (LS) and controlled attenuation parameter (CAP) measurements by Fibroscan allow assessing liver fat and fibrosis. Aim To determine the prevalence of steatosis and significant fibrosis in a comm...

Full description

Saved in:
Bibliographic Details
Published in:Liver international 2017-12, Vol.37 (12), p.1897-1906
Main Authors: Roulot, Dominique, Roudot‐Thoraval, Françoise, NKontchou, Gisele, Kouacou, Narcisse, Costes, Jean‐Luc, Elourimi, Ghassan, Le Clesiau, Hervé, Ziol, Marianne, Beaugrand, Michel
Format: Article
Language:English
Subjects:
Aged
Biopsy
Body weight
Cirrhosis
controlled attenuation parameter
Diabetes
Diabetes mellitus
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - epidemiology
Elasticity Imaging Techniques
Fatty liver
Fatty Liver - complications
Fatty Liver - diagnostic imaging
Fatty Liver - epidemiology
Fatty Liver - pathology
Female
Fibroscan
Fibrosis
France - epidemiology
Health risks
Humans
Liver
Liver - pathology
Liver cirrhosis
Liver Cirrhosis - complications
Liver Cirrhosis - diagnostic imaging
Liver Cirrhosis - epidemiology
Liver Cirrhosis - pathology
liver stiffness
Male
Middle Aged
Multivariate analysis
Overweight
Patients
Prevalence
Risk factors
screening
Steatosis
Stiffness
type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Type 2 diabetes is a risk factor for steatohepatitis and fibrosis. Non‐invasive liver stiffness (LS) and controlled attenuation parameter (CAP) measurements by Fibroscan allow assessing liver fat and fibrosis. Aim To determine the prevalence of steatosis and significant fibrosis in a community‐based diabetic population. Methods LS and CAP were measured in 705 patients using the standard “M probe.” A second “XL probe” was used, without CAP measurement, in case of failure with the “M probe.” Results LS and CAP measurements were obtained in 437 patients (the M group), LS measurements (LSM) with the XL probe being available in additional 232 patients. After the combined use of both probes, LSM failure and unreliable result were 1.6% and 5.6% respectively. Overall, 12.7% (n=85), 7.3% and 2.1% exhibited significant or advanced fibrosis or cirrhosis (LSM≥8 kPa, ≥9.6 kPa, ≥13 kPa respectively), half of the patients with LSM≥8 kPa displayed normal liver tests. Significant and severe steatosis were measured in 75% and 24% of the M group patients. By multivariate analysis, factors associated with severe fibrosis were age, overweight, high GGT. Forty‐seven patients with LSM≥8 kPa underwent liver biopsy; 93% had steatosis and 51% severe fibrosis. A significant correlation was found between LSM values and fibrosis score with an accuracy rate of 83%, 68% and 83% for LSM≥8 kPa, ≥9.6 kPa and ≥13 kPa respectively. Conclusions The prevalence of significant steatosis is very high and significant fibrosis affect 12.7% of the patients. Fibroscan is an effective procedure to screen for fibrosis and steatosis in diabetic patients.
ISSN:1478-3223
1478-3231
DOI:10.1111/liv.13481